Trial Profile

A Multi-center, Single Arm, Open-label Phase 1/2 Clinical Trial to Evaluate Safety, and to Explore Efficacy of TC011(CD19 Targeted CAR-T) in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TC 011 (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use
Acronyms TC011
Sponsors TICAROS

12 Mar 2026 New trial record
17 Nov 2024 According to Ticaros media release, Tikaros is conducting a phase 1 clinical trial of TC011 with clip CAR technology at Seoul National University Hospital, Severance Hospital, National Cancer Center, Bundang Seoul National University Hospital, and Samsung Seoul Hospital for patients with relapsed or refractory B-cell non-Hodgkins lymphoma.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com